Spots Global Cancer Trial Database for A Study of Propranolol to Treat Kaposi Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Propranolol to Treat Kaposi Sarcoma
Official Title: A Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Children and Adults
Study ID: NCT05797662
Conditions
Interventions
Study Description
Brief Summary: A clinical study of propranolol for the treatment of Kaposi Sarcoma in children and adults. This study will be an open-label single armed treatment trial that will test the effectiveness and the safety of treating Kaposi Sarcoma with propranolol.
Detailed Description: Eligible study participants will receive propanolol twice daily for an initial 12-week period. At the conclusion of 12-weeks, response will be assessed. Participants who achieve a complete or partial response will continue propanolol for an additional 6 weeks or 12 weeks, respectively.
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fundación Huésped, Buenos Aires, , Argentina
Instituto Nacional de Câncer José de Alencar, Rio De Janeiro, , Brazil
Complexo Hospitalar Universitário Professor Edgard Santos, Salvador, , Brazil
Moi University School of Medicine, Eldoret, , Kenya
UNC Project Malawi, Lilongwe, , Malawi
Instituto Nacional de Cancerologia, Ciudad de Mexico, , Mexico
African Cancer Institute at Stellenbosch, Cape Town, , South Africa
Uganda Cancer Institute, Kampala, , Uganda
University of Zimbabwe College of Health Sciences, Harare, , Zimbabwe
Contact Details
Name: Shane McAllister, Md, PhD
Affiliation: University of Minnesota Medical School Department of Pediatrics
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
